ADICET BIO INC (ACET)
US0070021086 - Common Stock
ACET gets a fundamental rating of 3 out of 10. The analysis compared the fundamentals against 612 industry peers in the Biotechnology industry. While ACET has a great health rating, there are worries on its profitability. ACET does not seem to be growing, but still is valued expensively.
1. Profitability
1.1 Basic Checks
In the past year ACET has reported negative net income.
In the past year ACET has reported a negative cash flow from operations.
In the past 5 years ACET always reported negative net income.
ACET had a negative operating cash flow in each of the past 5 years.
1.2 Ratios
ACET has negative profitability rations, so we won't be analyzing them here.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | N/A | ||
| ROE | N/A | ||
| ROIC | N/A |
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
ACET does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM | N/A | ||
| GM | N/A |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. Health
2.1 Basic Checks
ACET does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for ACET has been increased compared to 1 year ago.
ACET has more shares outstanding than it did 5 years ago.
ACET has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
2.2 Solvency
Based on the Altman-Z score of -1.22, we must say that ACET is in the distress zone and has some risk of bankruptcy.
Looking at the Altman-Z score, with a value of -1.22, ACET is in line with its industry, outperforming 53.81% of the companies in the same industry.
There is no outstanding debt for ACET. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Altman-Z | -1.22 |
ROIC/WACCN/A
WACC9.48%
2.3 Liquidity
ACET has a Current Ratio of 11.08. This indicates that ACET is financially healthy and has no problem in meeting its short term obligations.
The Current ratio of ACET (11.08) is better than 77.48% of its industry peers.
A Quick Ratio of 11.08 indicates that ACET has no problem at all paying its short term obligations.
The Quick ratio of ACET (11.08) is better than 77.65% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 11.08 | ||
| Quick Ratio | 11.08 |
3. Growth
3.1 Past
ACET shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -98.54%.
Looking at the last year, ACET shows a very negative growth in Revenue. The Revenue has decreased by -100.00% in the last year.
EPS 1Y-98.54%
EPS 3YN/A
EPS 5YN/A
EPS growth Q2Q-33.93%
Revenue growth 1Y-100%
Revenue growth 3YN/A
Revenue growth 5YN/A
Revenue growth Q2QN/A
3.2 Future
ACET is expected to show a small growth in Earnings Per Share. In the coming years, the EPS will grow by 7.73% yearly.
Based on estimates for the next years, ACET will show a very strong growth in Revenue. The Revenue will grow by 52.12% on average per year.
EPS Next Y-75.78%
EPS Next 2Y-28.03%
EPS Next 3Y-7.95%
EPS Next 5Y7.73%
Revenue Next Year-91.52%
Revenue Next 2Y-21.09%
Revenue Next 3Y3.75%
Revenue Next 5Y52.12%
3.3 Evolution
4. Valuation
4.1 Price/Earnings Ratio
The Price/Earnings Ratio is negative for ACET. In the last year negative earnings were reported.
Also next year ACET is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
A cheap valuation may be justified as ACET's earnings are expected to decrease with -7.95% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-28.03%
EPS Next 3Y-7.95%
5. Dividend
5.1 Amount
No dividends for ACET!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
ADICET BIO INC
NASDAQ:ACET (9/26/2023, 7:00:00 PM)
After market: 1.45 +0.02 (+1.4%)1.43
+0.03 (+2.14%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)08-09 2023-08-09/amc
Earnings (Next)11-06 2023-11-06/amc
Inst Owners90.64%
Inst Owner Change-1.51%
Ins Owners1.2%
Ins Owner Change8.94%
Market Cap61.58M
Analysts81.25
Price Target20.74 (1350.35%)
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-5.29%
Min EPS beat(2)-7.88%
Max EPS beat(2)-2.71%
EPS beat(4)1
Avg EPS beat(4)-40.55%
Min EPS beat(4)-153%
Max EPS beat(4)1.4%
Revenue beat(2)0
Avg Revenue beat(2)-100%
Min Revenue beat(2)-100%
Max Revenue beat(2)-100%
Revenue beat(4)0
Avg Revenue beat(4)-100%
Min Revenue beat(4)-100%
Max Revenue beat(4)-100%
PT rev (1m)-15.28%
PT rev (3m)-26.21%
EPS NQ rev (1m)-1.78%
EPS NQ rev (3m)-3.95%
EPS NY rev (1m)-5.02%
EPS NY rev (3m)-4.86%
Revenue NQ rev (1m)-99.9%
Revenue NQ rev (3m)-99.93%
Revenue NY rev (1m)8.01%
Revenue NY rev (3m)118.1%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | N/A | ||
| P/FCF | N/A | ||
| P/OCF | N/A | ||
| P/B | 0.26 | ||
| P/tB | 0.28 | ||
| EV/EBITDA | N/A |
EPS(TTM)-2.72
EYN/A
EPS(NY)-2.8
Fwd EYN/A
FCF(TTM)-2.27
FCFYN/A
OCF(TTM)-1.93
OCFYN/A
SpSN/A
BVpS5.55
TBVpS5.1
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | N/A | ||
| ROE | N/A | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM | N/A | ||
| GM | N/A | ||
| FCFM | N/A |
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score2
Asset Turnover0
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | N/A | ||
| Cap/Depr | 321.32% | ||
| Cap/Sales | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 11.08 | ||
| Quick Ratio | 11.08 | ||
| Altman-Z | -1.22 |
F-Score2
WACC9.48%
ROIC/WACCN/A
Cap/Depr(3y)526.82%
Cap/Depr(5y)447.63%
Cap/Sales(3y)68.92%
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
Growth
EPS 1Y-98.54%
EPS 3YN/A
EPS 5YN/A
EPS growth Q2Q-33.93%
EPS Next Y-75.78%
EPS Next 2Y-28.03%
EPS Next 3Y-7.95%
EPS Next 5Y7.73%
Revenue growth 1Y-100%
Revenue growth 3YN/A
Revenue growth 5YN/A
Revenue growth Q2QN/A
Revenue Next Year-91.52%
Revenue Next 2Y-21.09%
Revenue Next 3Y3.75%
Revenue Next 5Y52.12%
EBIT growth 1Y-166.57%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-182.11%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-85.12%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-69.39%
OCF growth 3YN/A
OCF growth 5YN/A